307 related articles for article (PubMed ID: 8055460)
1. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation.
Greven KM; Williams DW; Keyes JW; McGuirt WF; Watson NE; Randall ME; Raben M; Geisinger KR; Cappellari JO
Cancer; 1994 Aug; 74(4):1355-9. PubMed ID: 8055460
[TBL] [Abstract][Full Text] [Related]
2. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma.
Wong WL; Chevretton EB; McGurk M; Hussain K; Davis J; Beaney R; Baddeley H; Tierney P; Maisey M
Clin Otolaryngol Allied Sci; 1997 Jun; 22(3):209-14. PubMed ID: 9222623
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy.
Chaiken L; Rege S; Hoh C; Choi Y; Jabour B; Juillard G; Hawkins R; Parker R
Int J Radiat Oncol Biol Phys; 1993 Sep; 27(2):455-64. PubMed ID: 8407422
[TBL] [Abstract][Full Text] [Related]
5. The role of positron emission tomography in occult primary head and neck cancers.
Safa AA; Tran LM; Rege S; Brown CV; Mandelkern MA; Wang MB; Sadeghi A; Juillard G
Cancer J Sci Am; 1999; 5(4):214-8. PubMed ID: 10439166
[TBL] [Abstract][Full Text] [Related]
6. Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose.
Greven KM; Keyes JW; Williams DW; McGuirt WF; Joyce WT
Cancer; 1999 Jul; 86(1):114-8. PubMed ID: 10391570
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomographic imaging of head and neck lesions.
Sakamoto H; Nakai Y; Ohashi Y; Okamura T; Ochi H
Eur Arch Otorhinolaryngol; 1997; 254 Suppl 1():S123-6. PubMed ID: 9065645
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapeutic management of head and neck malignancies with positron emission tomography.
Reisser C; Haberkorn U; Dimitrakopoulou-Strauss A; Seifert E; Strauss LG
Arch Otolaryngol Head Neck Surg; 1995 Mar; 121(3):272-6. PubMed ID: 7873142
[TBL] [Abstract][Full Text] [Related]
9. Distinguishing tumor recurrence from irradiation sequelae with positron emission tomography in patients treated for larynx cancer.
Greven KM; Williams DW; Keyes JW; McGuirt WF; Harkness BA; Watson NE; Raben M; Frazier LC; Geisinger KR; Cappellari JO
Int J Radiat Oncol Biol Phys; 1994 Jul; 29(4):841-5. PubMed ID: 8040032
[TBL] [Abstract][Full Text] [Related]
10. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
[TBL] [Abstract][Full Text] [Related]
11. Fluorine-18 fluorodeoxyglucose imaging using dual-head coincidence positron emission tomography without attenuation correction in patients with head and neck cancer.
Pai M; Park CH; Suh JH; Koh JH
Clin Nucl Med; 1999 Jul; 24(7):495-500. PubMed ID: 10402001
[TBL] [Abstract][Full Text] [Related]
12. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment.
Yao M; Smith RB; Graham MM; Hoffman HT; Tan H; Funk GF; Graham SM; Chang K; Dornfeld KJ; Menda Y; Buatti JM
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):991-9. PubMed ID: 16099601
[TBL] [Abstract][Full Text] [Related]
13.
Cheol Park G; Roh JL; Cho KJ; Seung Kim J; Hyeon Jin M; Choi SH; Yuhl Nam S; Yoon Kim S
Int J Cancer; 2017 Mar; 140(6):1405-1412. PubMed ID: 27943271
[TBL] [Abstract][Full Text] [Related]
14. Occult primary tumors of the head and neck: detection with 2-[F-18] fluoro-2-deoxy-D-glucose SPECT.
Mukherji SK; Drane WE; Mancuso AA; Parsons JT; Mendenhall WM; Stringer S
Radiology; 1996 Jun; 199(3):761-6. PubMed ID: 8638002
[TBL] [Abstract][Full Text] [Related]
15. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas.
Laubenbacher C; Saumweber D; Wagner-Manslau C; Kau RJ; Herz M; Avril N; Ziegler S; Kruschke C; Arnold W; Schwaiger M
J Nucl Med; 1995 Oct; 36(10):1747-57. PubMed ID: 7562038
[TBL] [Abstract][Full Text] [Related]
16. Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography.
Farber LA; Benard F; Machtay M; Smith RJ; Weber RS; Weinstein GS; Chalian AA; Alavi A; Rosenthal DI
Laryngoscope; 1999 Jun; 109(6):970-5. PubMed ID: 10369292
[TBL] [Abstract][Full Text] [Related]
17. The impact of FDG PET on the management of occult primary head and neck tumours.
Wong WL; Saunders M
Clin Oncol (R Coll Radiol); 2003 Dec; 15(8):461-6. PubMed ID: 14690001
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of positron emission tomography with 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck.
Fischbein NJ; AAssar OS; Caputo GR; Kaplan MJ; Singer MI; Price DC; Dillon WP; Hawkins RA
AJNR Am J Neuroradiol; 1998 Aug; 19(7):1189-96. PubMed ID: 9726451
[TBL] [Abstract][Full Text] [Related]
19. Preoperative evaluation of patients with primary head and neck cancer using dual-head 18fluorodeoxyglucose positron emission tomography.
Stokkel MP; ten Broek FW; Hordijk GJ; Koole R; van Rijk PP
Ann Surg; 2000 Feb; 231(2):229-34. PubMed ID: 10674615
[TBL] [Abstract][Full Text] [Related]
20. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers.
Rege S; Maass A; Chaiken L; Hoh CK; Choi Y; Lufkin R; Anzai Y; Juillard G; Maddahi J; Phelps ME
Cancer; 1994 Jun; 73(12):3047-58. PubMed ID: 8200003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
